About

Precision radio­pharma­ceuticals

Precirix is a private biotechnology company dedicated to extending and improving the lives of cancer patients by designing and developing novel radiopharmaceuticals, using camelid-derived single-domain antibodies (sdAb) labeled with radioisotopes.

CAM-H2, a HER2-directed sdAb combined with iodine-131 recently completed a Phase I clinical study. The company’s Fibroblast Activation Protein (FAP)-targeting program is transitioning into the clinic.

The company’s technology platform allows for a theranostic approach, using the same molecule for patient selection (imaging) and therapy. In addition to CAM-FAP and CAM-H2, the company has product candidates in preclinical stage and is further broadening its platform through research on isotopes, linker technology and combination therapies.